Friday 16 October 2026
Export CUE’s income statement to Excel — free account
Cue Biopharma, Inc.
Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024. In the quarter to June 2026, revenue grew 166.7%, EPS fell 793.2% and free cash flow fell 742.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
16.96
1.71
−9.16%
Follow CUE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (1,603.48%) | (138.52%) | (121.11%) | (195.19%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
3 | 4 | 5 | 3 | |
| (459.60%) | (73.49%) | (71.51%) | (98.58%) | ||
ROIC |
0.00% | (294.07%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(2,899.43%) | (101.21%) | (112.10%) | (355.43%) | |
Average Days of Receivables |
52.12 | 59.67 | 73.70 | 19.90 | |
Free Cash Flow per Share |
(7.91) | (5.11) | (6.92) | (8.87) | |
Free Cash Flow |
(50.13) | (24.56) | (21.82) | (29.80) | |
Capital Expenditures |
(0.08) | (0.11) | (0.14) | (0.16) | |
| Other line items | |||||
Cash ROIC |
(254.14%) | (62.91%) | (39.93%) | (84.38%) | |
Accounts Receivable Turnover |
12.74 | 10.40 | 6.32 | 6.36 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
205.00% | 110.27% | 137.42% | 399.94% | |
Selling, General and Administrative Expense of Revenue |
156.98% | 49.56% | 59.14% | 236.79% | |
Share Based Compensation of Revenue |
69.13% | 10.55% | 17.27% | 80.23% | |
Interest Coverage |
(511.22) | (84.15) | (74.38) | (95.41) | |
Operating CF/Net income |
0.31 | 1.25 | 0.82 | 0.79 | |
Depreciation/Fixed assets |
4.58 | 4.19 | 3.25 | 0.76 | |
Capex/Depreciation |
(0.07) | (0.09) | (0.17) | (0.68) | |
Revenue per Share |
5.94 | 6.81 | 8.71 | 2.11 | |
Operating CF per Share |
(7.89) | (5.09) | (6.87) | (8.82) | |
Capex per Share |
(0.01) | (0.02) | (0.04) | (0.05) | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.02 |
Columns are period end dates